25x-NBOMe: Difference between revisions
>BronzeManul Replaced substitutive skeletal structure image with standardised svg image. |
>Blackhole removed substance class |
||
(11 intermediate revisions by 7 users not shown) | |||
Line 31: | Line 31: | ||
|- | |- | ||
| [[25N-NBOMe]] || NO<sub>2</sub> || [[File:25N-NBOMe.svg|200px]] | | [[25N-NBOMe]] || NO<sub>2</sub> || [[File:25N-NBOMe.svg|200px]] | ||
|- | |||
| 25iP-NBOMe || CH(CH<sub>3</sub>)<sub>2</sub> || [[File:25iP-NBOMe.svg|200px]] | |||
|- | |- | ||
|} | |} | ||
Line 40: | Line 42: | ||
Tolerance to the effects of any member of the 25x-NBOMe series is built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::1 week]] for the tolerance to be reduced to half and [[Time to zero tolerance::2 weeks]] to be back to baseline (in the absence of further consumption). Members of the 25x-NBOMe series present cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the consumption of any member of the 25x-NBOMe series all psychedelics will have a reduced effect. | Tolerance to the effects of any member of the 25x-NBOMe series is built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::1 week]] for the tolerance to be reduced to half and [[Time to zero tolerance::2 weeks]] to be back to baseline (in the absence of further consumption). Members of the 25x-NBOMe series present cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the consumption of any member of the 25x-NBOMe series all psychedelics will have a reduced effect. | ||
===Overdose=== | |||
{{NBOMeOD}} | |||
===Dangerous interactions=== | ===Dangerous interactions=== | ||
{{DangerousInteractions/Intro}} | {{DangerousInteractions/Intro}} | ||
{{DangerousInteractions/NBOMe}} | |||
====[[Serotonin syndrome]] risk==== | ====[[Serotonin syndrome]] risk==== | ||
Line 53: | Line 55: | ||
==Legal status== | ==Legal status== | ||
{{legalStub}} | {{legalStub}} | ||
*'''Austria:''' The 25x-NBOMe family is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).{{citation needed}} | |||
*'''Poland:''' The 25x-NBOMe family is controlled by Group I-P in "Act of 29 July 2005 on preventing drug addictions" (Ustawa z dnia 29 lipca 2005 o przeciwdziałaniu narkomanii).{{citation needed}} | |||
*'''United States:''' In the US, some of the 25x-NBOMe chemicals are listed as Schedule I substances and others may be considered analogues under the Federal Analogue Act.{{citation needed}} | *'''United States:''' In the US, some of the 25x-NBOMe chemicals are listed as Schedule I substances and others may be considered analogues under the Federal Analogue Act.{{citation needed}} | ||
*'''United Kingdom''' | *'''United Kingdom:''' The majority of synthesised 25x-NBOMe substances are Class A drugs in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.<ref>United Kingdom. (2014). Misuse of Drugs Act 1971 (S.I. 2014/1106). London: The Stationery Office Limited. Retrieved July 5, 2017, from http://www.legislation.gov.uk/uksi/2014/1106/made</ref> Any compounds not covered by the clause are illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26th, 2016.<ref>Psychoactive Substances Act 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted</ref> | ||
==See also== | ==See also== | ||
Line 63: | Line 67: | ||
*[[2C-x]] | *[[2C-x]] | ||
*[[DOx]] | *[[DOx]] | ||
==External links== | |||
*[https://en.wikipedia.org/wiki/25-NB 25-NB (Wikipedia)] | |||
*[https://erowid.org/chemicals/nbome/nbome.shtml NBOMe Series (Erowid Vault)] | |||
==Literature== | ==Literature== | ||
Line 71: | Line 80: | ||
==References== | ==References== | ||
<references /> | <references /> | ||
[[Category:Chemical class]] | |||
[[Category:25x-NBOMe|*]] |